Why Novavax Stock Is Up By 6% Today

Novavax Stock Rallies After Company Gets Emergency Use Authorization For COVID-19 Vaccine In India

Shares of Novavax gained strong upside momentum after the company received an emergency use authorization for its coronavirus vaccine in India.

Novavax stock has been very volatile in recent months and traded in a wide range between the lows near $120, that were reached back in October, and the highs near $235, that were reached a week ago.

It should be noted that other vaccine stocks like Moderna and BioNTech have also experienced significant volatility. It looks that traders are concerned about sustainability of current revenue and profits.

New anti-viral drugs appeared in the market, and there are hopes that Omicron, which has already became the dominant variant in the U.S. according to CDC, may be less dangerous than Delta. In this environment, market sentiment shifts quickly, which is visible in the recent dynamics of Novavax stock.

What’s Next For Novavax Stock?

Analysts expect that Novavax will report a loss of $12.12 per share in the current year and a profit of $25.71 per share in the next year, so the stock is trading at less than 7 forward P/E.

As I mentioned above, the key problem for Novavax and other vaccine stocks is poor earnings visibility. In addition, earnings estimates for the next year have been steadily declining, which served as an additional bearish catalyst for Novavax stock.

While Novavax is cheaper than its peers, the discount is not dramatic, so it remains to be seen whether speculative traders will choose Novavax stock over the above-mentioned Moderna or BioNTech if they decide to bet on the rebound of the segment.

In recent weeks, we have seen some rush to safety, and bigger, diversified players like AstraZeneca and Pfizer had good stock price dynamics while shares of  non-diversified vaccine makers found themselves under pressure. If this trend continues, shares of Novavax will move lower despite good news from India.

For a look at all of today’s economic events, check out our economic calendar.

What Fuels The Stock Market Now?

An outstanding earnings season and signs that economic activity are picking back up are clashing with unrelenting inflation, difficulty finding more labor, and continued supply chain logjams.


Most insiders believe inflation has further to climb, though the consensus right now is calling for a peak around the beginning of Q2 next year. With big shopping holidays in the U.S. coming up, followed closely by Chinese New Year at the beginning of February 2022, shipping and transportation logjams aren’t expected to find much relief in the near-term.

Meaning inflation pressures will likely continue. How far inflation will climb as the severe supply chain dislocations drag on is a huge unknown. Some Wall street investors are concerned that the Fed might feel compelled to end its asset purchases and hike rates much sooner than expected if monthly inflation keeps accelerating.

What might be even more worrisome is the fear that some of these price increases could be more permanent in nature, so how much overall inflation will pull back in the long run is starting to become a bigger talking point.

Demand and supply chain

Supply chain insiders warn that many companies are front-loading inventories in an effort to avoid running out of critical materials, which could bite in the long run if demand suddenly drops off. A lot of manufacturers have also increased production capacity for products that currently face shortages. The risk is that once back orders are filled and demand retreats, stockpiling and excess production could result in an oversupply situation in some areas, along with much lower profits and total revenues.

Another worry right now is that demand starts to retreats due to the current inflationary environment especially with everyday items like food and gasoline costing substantially more. That has investors anxious to see the latest Consumer Sentiment read being released today which is expected to edge higher vs. last month.

Investors are closing tracking the inflation expectation gauges in the report as typically the higher those climb, the more consumers tend to pull back on spending.

Data to watch next week

Looking towards next week, the economic data flow picks up with key releases including Empire State Manufacturing on Monday; Retail Sales, Import/Export Prices, Industrial Production, Business Inventories, and the NAHB Housing Market Index on Tuesday; Housing Starts and Building Permits on Wednesday; and the Philadelphia Fed Index on Thursday.

On the earnings front, Q3 reporting is just about wrapped up with companies in the S&P 500 index reporting revenue growth of more than +17%, the second highest on record behind only Q2 2021’s growth of over +25%, according to FactSet. Earnings themselves are on track to exceed +40%. AstraZeneca is today’s earnings highlight. Earnings next week include several big retailers which will provide some more clues as to how consumer demand is trending as well as updates on supply chain struggles. Investors are also keen to hear how holiday hiring is going.

Key earnings reports next week will include Advanced Auto Parts, Lucid, Tyson, and Warner Music on Monday; Home Depot and Walmart on Tuesday; Bath & Body Works, Cisco, Lowe’s, NVIDIA, Target, TJX, and Victoria’s Secret on Wednesday; Alibaba, Applied Materials, Intuit, Kohl’s, Macy’s, Palo Alto Networks, Ross Stores, and Williams Sonoma on Thursday; and The Buckle and Foot Locker on Friday.

Checking in on the geopolitical front, the U.S. is warning that Russia may be planning a full-scale invasion of Ukraine. U.S. officials say they’ve briefed their EU counterparts about concerns over a possible military operation, citing a buildup of Russian troops along the Ukraine border. Tensions are boiling still in Belarus and Russia is fanning the flames on that front as well.

SP500 commentary

ES ##-## (Daily) 2021_11_14 (1_49_54 AM)

The bearish accumulation divergence played very well last week. Moreover, the Advance Decline Line is weaker than the price is. It is also a negative factor in the short term. Potentially SP500 started the formation of the bull flag. Finding support at lower levels would be a great buying point with a target of 4800.

The major economic indicators are still bullish despite rising inflation. 4500 level is a psychological level bears will target if 4600 fails. Current levels can be considered only for intraday trading. At the same time, lower levels are needed to get a good risk/reward ratio for swing traders.

For a look at all of today’s economic events, check out our economic calendar.

Why AstraZeneca Stock Is Down By 6% Today

AstraZeneca Stock Declines After Earnings Report

Shares of AstraZeneca found themselves under significant pressure after the company released its quarterly results.

AstraZeneca reported revenue of $9.87 billion and adjusted earnings of $1.08 per share, beating analyst estimates on both earnings and revenue. However, the company’s GAAP loss of $1.10 per share missed analyst estimates by a wide margin, which served as a negative catalyst for the stock.

The company reiterated its full-year guidance, but it looks that the market expected that it would set more aggressive targets.

AstraZeneca has also stated that it would begin to sell its coronavirus vaccine for a profit. In the quarter, COVID-19 vaccine added $0.01 to the company’s EPS, and AstraZeneca expects that vaccine’s contribution to earnings will gradually increase in the upcoming quarters, although its contribution in the fourth quarter of this year will be limited.

What’s Next For AstraZeneca Stock?

AztraZeneca is projected to report earnings of $3.27 this year and $3.98 per share in the next year, so the stock is trading at 15 forward P/E.

It looks that the market does not believe that the company’s coronavirus vaccine will be able to materially boost its profits as the market is dominated by vaccines from Pfizer and Moderna. In addition, the market has recently became more cautious towards vaccine makers due to low visibility of vaccine-related earnings after 2022.

It should be noted that AstraZeneca stock is trading at a premium to Pfizer stock, and it remains to be seen whether this premium is justified. Current valuation levels do not look to cheap so multiple compression is possible, which is bearish for the stock. AstraZeneca shares have recently traded near yearly highs so opportunistic traders may choose to wait for additional pullback before initiating new positions in the stock.

For a look at all of today’s economic events, check out our economic calendar.

Preview: What to Expect From AstraZeneca’s Q3 Earnings on Friday

The British-Swedish pharmaceutical giant AstraZeneca is expected to report earnings per share of GBP 92.54 in the third quarter on revenue of GBP 7.04 billion.

The one listed on the U.S. exchange was expected to report revenue growth of over 50% to $9.871 billion from $6.58 billion seen in the same period a year earlier. The earnings per share (EPS) was expected to rise to $0.62 from $0.47 a year ago.

“We estimate Q3 EPS of $1.23 (+31%) vs. consensus of $1.24. We forecast total Q3 revenue of $9.85B (+50%) vs. consensus of $9.62B. Collaboration revenue is estimated to contribute $80MM. Q3 estimates of key products include: Tagrisso (+19% to $1,370MM), Imfinzi (+28% to $685MM), Lynparza (+36% to $630MM), and Fasenra (+44% to $345MM),” noted Steve Scala, equity analyst at Cowen.

The London-listed AstraZeneca shares rose nearly 30% so far this year. It was trading 1.04% higher at GBX 9,386 at the time of writing on Wednesday. AstraZeneca’s better-than-expected third-quarter earnings results, which will be announced on Friday, November 12, could help the stock scale to a fresh record high.

Analyst Comments

“We expect Q3’21 sales to reflect lower levels of cancer diagnoses and VBP pressures in China, with the gross margin continuing to be impacted by COVID-19 vaccine sales and changes in product mix. With collaboration revenues / OOI phased into 4Q21, consensus Q3’21 earnings appear c.8% too high,” noted Mark Purcell, equity analyst at Morgan Stanley.

“Sector leading growth: The acquisition of Alexion should accelerate revenue growth to 8% CAGR FY22-25e, whilst strengthening the therapeutic and geographic diversification of the group. After reflecting cost synergies, we project ~15% earnings CAGR FY22-25e vs. ~8% for peers. Product & pipeline optionality: We see a further 20-30% upside risk to cons. expectations from new product launches. In addition, we see near-term upside from the pipeline, where positive readouts could drive MSD upside to cons. mid-term earnings. Valuation is compelling: Currently trading on~16x FY’22e P/E/at a 40% discount to close comparator Novo, despite offering stronger and arguably more diversified growth.”

AstraZeneca Stock Price Forecast

Thirteen analysts who offered stock ratings for AstraZeneca in the last three months forecast the average price in 12 months of GBX 9,596.25 with a high forecast of GBX 15,000.00 and a low forecast of GBX 105.00.

The average price target represents a 2.26% change from the last price of 9,384.00p. All of those 13 analysts rated “Buy”, according to Tipranks.

Morgan Stanley gave the base target price of GBX 10,000 with a high of GBX 12,000 under a bull scenario and GBX 6,900 under the worst-case scenario. The firm gave an “Overweight” rating on the pharmaceutical company’s stock.

Several other analysts have also updated their stock outlook. UBS raised the target price to GBX 10,000 from GBX 9,200. Guggenheim lifted the target price to GBX 11,100 from GBX 11,000. HSBC upped the target price to GBX 8,750 from GBX 7,131.

Technical analysis suggests it is good to buy now as 100-day Moving Average, and 100-200-day MACD Oscillator signals a strong buying opportunity.

Check out FX Empire’s earnings calendar

Earnings Week Ahead: PayPal, Middleby, Walt Disney and AstraZeneca in Focus

Earnings Calendar For The Week Of November 8

Monday (November 8)


The leading global payments company PayPal will post earnings of $1.07 per share in the third quarter, more or less in line with the reading seen in the same period a year ago. San Jose, California-based company would post revenue growth of about 14% to around $6.2 billion.

PayPal estimates revenues of about $6.15 billion to $6.25 billion during the third quarter of 2021, up by 13-14% from the previous quarter. The company anticipates non-GAAP earnings per share of $1.07 during Q3 of 2021.

PayPal, one of our top OWs (Overweight), is the preferred digital wallet option for non-Amazon merchants, as evidenced by its online acceptance lead vs. other digital wallets and industry-low attrition. PayPal’s efforts to offer a seamless and secure checkout experience ties its TPV growth rate with the secular growth of eCommerce. As consumers increase their habitual use of PayPal, the company should grow its TPV at or above the rate of eCommerce (ex-Amazon),” noted James Faucette, equity analyst at Morgan Stanley.

“Venmo, POS and partnership monetization could offer additional TPV and revenue growth, while operating leverage from its scale support 20%+ earnings growth over the medium term, despite near-term headwinds from eBay and macro impacts.”


Ticker Company EPS Forecast
FIVN Five9 $0.24
THS TreeHouse Foods $0.50
BKI Black Iron Inc. $0.57
COTY Coty $0.02
AEIS Advanced Energy Industries $0.82
AMRS Amyris -$0.15
SANM Sanmina $0.99
AU Anglogold Ashanti $0.36
MRTX Mirati Therapeutics -$2.88
CTRE CareTrust REIT $0.20
PSEC Prospect Capital $0.18
AMC AMC Entertainment -$0.53
VAC Marriottacations Worldwide $1.42
JKHY Jack Henry Associates $1.32
PRI Primerica $2.98
NNI Nelnet $1.68
OSH Oak Street Health -$0.42
ACAD Acadia Pharmaceuticals -$0.26
FSK FS KKR Capital $0.61
MWA Mueller Water Products $0.19
AEL American Equity Investment Life $0.76
PRAA PRA $0.73
DOOR Masonite International $1.87
TRIP TripAdvisor $0.24
NHI National Health Investors $0.98
TREX Trex $0.58
IFF International Flavors Fragrances $1.37
ENV Envestnet $0.58
TWO Two Harbors Investment $0.19
CBT Cabot $1.03
PYPL PayPal $1.07

Tuesday (November 9)


Middleby, a global leader in the foodservice equipment industry, is expected to report earnings of $2.03 in the third quarter, which represents year-over-year growth of over 50% from $1.34 per share seen in the same period a year ago.

The U.S. foodservice equipment maker will report revenue of $837.32 million, up 32% from the same period a year ago. It is worth noting that the company has always surpassed consensus earnings estimates in the last four quarters.

“The outlook for MIDD appears positive heading into 3Q21 earnings next week, with ITW Food Equipment seeing ~50% growth in restaurant revenue and JBT Foodtech generating+15% organic growth. Restaurant commentary points to investment activity centred around increasing efficiency/productivity, although we could see new builds pushed out due to labour/supply chain constraints,” noted Saree Boroditsky, an equity analyst at Jefferies.


Ticker Company EPS Forecast
HAIN Hain Celestial $0.24
IGT International Game Technology $0.53
JHX James Hardie Industries $0.32
HAE Haemonetics $0.61
IIVI Ii Vi $0.83
FSS Federal Signal $0.46
TAC TransAlta USA $0.11
STWD Starwood Property $0.52
CAH Cardinal Health $1.33
PLTR Palantir Technologies Inc. $0.04
DHI DR Horton $3.39
SGMS Scientific Games $0.37
ELY Callaway Golf $0.03
OCGN Ocugen -$0.04
SEAS SeaWorld Entertainment $1.66
SATS EchoStar $0.33
ITCI Intra Cellular Therapies -$0.90
MIDD Middleby $2.03
EC Ecopetrol $2,315.76
ADT ADT $0.08
SYY Sysco $0.86
G Genpact $0.56
JAZZ Jazz Pharmaceuticals $3.31
RNG RingCentral $0.33
TTEC TeleTech $0.84
NSTG NanoString Technologies -$0.55
LGND Ligand Pharmaceuticals $1.07
BAK Braskem $2.34
EPAY Bottomline Technologies $0.25
PAAS Pan American Silver USA $0.35
NUVA NuVasive $0.54
CNNE Cannae $0.09
COKE Coca Cola Bottlingconsolidated $7.86
PAY VeriFone Systems $0.01
CCXI ChemoCentryx -$0.45
SWX Southwest Gas $0.13
DAR Darling Ingredients $0.82
ASH Ashland $1.34
EDU New Oriental Education Tech -$0.05
GOL Gol Linhas Aereas Inteligentes -$1.01

Wednesday (November 10)


Walt Disney, a family entertainment company, is expected to report its fiscal fourth-quarter earnings of $0.44 per share, which represents year-over-year growth of over 320% from a loss of -$0.20 per share seen in the same period a year ago.

The family entertainment company would post revenue growth of 28% to $18.8 billion. The company has beaten earnings per share (EPS) estimates all times in the last four quarters, according to ZACKS Research.

As of July, Disney+ and Hotstar had more than 116 million subscribers, while Hulu and ESPN+ combined had more than 57 million subscribers. Barclays analysts cite slowing growth and the fact that Disney+ produces far less new content than Netflix, as reasons for their scepticism. Disney+ claims to have 250 million subscribers by 2024, Fobes reported.

“We see Disney on the shortlist of global streaming majors. Despite significant continued upward earnings revisions, shares have lagged as net adds expectations ran ahead of content deliveries. As the content pipeline builds into ’22 and ’23, core net adds should accelerate, driving shares,” noted Benjamin Swinburne, equity analyst at Morgan Stanley.

Disney is building content assets that enable it to take advantage of the significant direct-to-consumer streaming opportunity ahead. Disney’s underlying IP remains best-in-class, supporting long term content monetization opportunities. During this period of FCF pressure from Parks closures, ESPN’s FCF generation is key to driving down leverage. Historical cycles suggest a potential return to above prior peak US Parks revenues in FY23.”


Ticker Company EPS Forecast
AY Atlantica Yield $0.60
PRGO Perrigo $0.65
ADNT Adient PLC -$0.75
WWW Wolverine World Wide $0.61
ENR Energizer $0.72
GIB CGI Group USA $1.08
AER AerCap $2.22
ELP Companhia Paranaense De Energia $0.66
MSGS Madison Square Garden Sports -$1.30
PAM Pampa Energia $0.93
BRKS Brooks Automation USA $0.77
YPF YPF $0.31
ENS Enersys $1.07
EBR Centrais Eletricas Brasileiras $0.25
FICO Fair Isaac $3.18
CCMP Cabot Microelectronics $1.87
DIS Walt Disney $0.52
BRFS BRF $0.03
ATO Atmos Energy $0.34
KGC Kinross Gold USA $0.06

Thursday (November 11)

Ticker Company EPS Forecast
CAE Cae USA $0.16
GFI Gold Fields $0.21
AEG Aegon -$0.02
TPR Tapestry Inc $0.70
BAM Brookfield Asset Management USA $0.83
EPC Edgewell Personal Care $0.84
UTZ Utz Brands $0.16
FLO Flowers Foods $0.25
CELH Celsius $0.06
SBH Sally Beauty $0.52
MT Arcelormittal $4.01
PVG Pretium Resources $0.16
SBS Companhia De Saneamento Basico $0.19
BLFS BioLife Solutions -$0.07

Friday (November 12)


The British-Swedish pharmaceutical giant AstraZeneca is expected to report earnings per share of GBP 92.54 in the third quarter on revenue of GBP 7.04 billion.

“We expect Q3’21 sales to reflect lower levels of cancer diagnoses and VBP pressures in China, with the gross margin continuing to be impacted by COVID-19 vaccine sales and changes in product mix. With collaboration revenues / OOI phased into 4Q21, consensus Q3’21 earnings appear c.8% too high,” noted Mark D Purcell, equity analyst at Morgan Stanley.


Ticker Company EPS Forecast
MFG Mizuho Financial $0.08
SMFG Sumitomo Mitsui Financial $0.20
CIG Companhia Energetica Minas Gerais $0.07
SPB Spectrum Brands $0.79
ROLL Rbc Bearings $1.05


Weaker Sterling Boosts FTSE, Barclays Slides as CEO Steps Down

Barclays was down 2.7% in early deals after it said CEO Jes Staley is to stand down following British regulators’ investigations into his ties with convicted sex offender Jeffrey Epstein.

The FTSE 100 index gained 0.3% by 08:10 GMT, with drugmakers AstraZeneca and GlaxoSmithKline among the top boosts.

Investor focus now is on the Bank of England meeting on Thursday, with a better-than-even chance of the central bank raising interest rates for the first time since the pandemic. [BOEWATCH].

The domestically focussed mid-cap index advanced 0.3%.

Commercial landlord Land Securities Group gained 0.7% after it announced plans to buy the property regeneration firm U and I Group for 190 million pounds ($259.46 million).

(Reporting by Bansari Mayur Kamdar in Bengaluru; Editing by Shounak Dasgupta)


FTSE 100 Falls on Rate Hike Worries; Playtech Soars

By Shashank Nayar and Bansari Mayur Kamdar

The blue-chip FTSE 100 index declined 0.1% by 08:10 GMT, with AstraZeneca and Diageo PLC being among the top losers.

Softbank-backed online retailer and tech group, The Hut Group, rose 8.4% after saying it would remove its founder’s “golden share” and seek a place on the premium segment of the main stock market.

A survey of chief financial officers at top British companies found that they expect supply chain problems in the UK to persist for at least another year and consumer price inflation to still be above 2.5% in two years’ time.

Supply worries and rising energy costs have slowed the pace of gains on the FTSE 100 recently and led the benchmark index to underperform developed market peers in Europe and the United States.

While U.S. and the wider European stock aggregate have hit multiple record highs this year, the FTSE 100 is around 8% away from all-time highs that were last hit in May 2018.

“If consumers are facing higher energy prices and higher prices of goods in the shops, they may start to become less spend-happy, buying less at some point, which then could have an impact on companies,” said Susannah Streeter, market analyst at Hargreaves Lansdown.

The domestically focussed mid-cap index was unchanged.

Investor sentiment also took a hit after data showed China’s economy grew more slowly than expected in the third quarter, clouding the global recovery outlook.

Gaming software supplier Playtech Plc soared 58% after Australia’s Aristocrat Leisure Ltd said it will buy the company for 2.1 billion pounds ($2.89 billion).

British transport group National Express and its takeover target Stagecoach Group dropped 1.7% and 2.1%, respectively, after the regulator extended the deadline until Nov. 16 for National Express to make a firm offer.

(Reporting by Bansari Mayur Kamdar; editing by Uttaresh.V)

Moderna Could Offer Low-Risk Buying Opportunity

Moderna Inc. (MRNA) fell 11.4% on Friday after Dow component Merck and Co. Inc. (MRK) announced positive clinical results for a pill to reduce COVID-19 hospitalizations and death. If emergency use is approved, patients can take the pill after infection but it won’t replace the billions of vaccinations still needed to inoculate the planet. The decline added to a string of losses since late September, bringing the total weekly loss to a staggering 19.44%.

The Pure COVID Play

MRNA’s float is just 344 million shares, far lower than the billions at Merck, Pfizer Inc. (PFE), and AstraZeneca PLC (AZN), generating volatile price action that’s highly levered to pandemic catalysts, positive and negative. In fact, shareholders have been whipsawed by price swings of 80 points or more, higher and lower, four times since the end of July. Unfortunately, accumulation has deteriorated badly on the latest downturn, exposing the stock to a deep Q4 correction.

However, the future is bright for the Cambridge, MA juggernaut, which holds the most important biotech patents since statins hit the market in the 1980s. The company announced a host of “significant advances across its growing portfolio” at a Research and Development Day last month, with ongoing trials and treatments for the COVID booster, RSV + hMPV, Epstein-Barr, and forms of cancer. In addition, it announced that 37 programs are now in development, including 22 in ongoing clinical studies.

Wall Street and Technical Outlook

Wall Street consensus is mixed after Moderna’s historic gains, with a ‘Hold’ rating based upon 5 ‘Buy’, 7 ‘Hold’, and 1 ‘Underweight’ recommendation. In addition, three analysts recommend that shareholders close positions and move to the sidelines. Price targets range from a low of $85 to a Street-high $485 while the stock closed Friday’s session more than $100 below the median $453 target. It’s instructive to note that analysts have been horrifically wrong about the pandemic’s trajectory since the start of 2020.

Moderna came public at 22 in 2018 and traded in a range between 11 and 30 into 2020 when it broke out in a powerful but highly volatile uptrend. It cleared resistance in the 80s in November and another barrier at 160 in June 2021, entering a final wave that posted an all-time high at 497.49 in August. The stock just broke down from a double top pattern, favoring downside that could offer a low-risk buying opportunity at the unfilled July gap between 260 and 271.

For a look at this week’s economic events, check out our economic calendar.

Disclosure: the author held no positions in aforementioned securities at the time of publication. 

AstraZeneca Exploring Options for COVID-19 Vaccine Business

By Alistair Smout and Pushkala Aripaka

The review of the future of the vaccine comes after a series of setbacks in its race to produce a shot for the world. Executives emphasised it was too early to say what the decision on the vaccine’s future would be.

AstraZeneca agreed to work with the University of Oxford on its COVID-19 shot last year despite having no prior vaccine experience, taking on the project with a pledge not to make a profit during the coronavirus pandemic.

While a $39 billion dollar deal to buy rare drug firm Alexion is much more integral to the company’s business strategy, the COVID-19 vaccine has quickly become the public face of the company’s efforts during the coronavirus pandemic.

“A small group of people reporting into Mene (Pangalos, research chief) and myself are thinking about: is this a sustainable business?” AstraZeneca Executive Vice President and President of the BioPharmaceuticals Business Unit Ruud Dobber said, referring to the vaccines business.

“We need to have that discussion with our senior executive team, and then with the board of AstraZeneca. We are exploring different options, but it is far too early at this stage to conclude that (process).”

Dobber added that “before year-end, we will have more clarity”.

“Hopefully before the year ends, we will have a better view how to move forward in the next few years,” he said.

“If you ask me, is the vaccine business a sustainable business for AstraZeneca for the next five or 10 years, that big strategic question is under discussion.”


AstraZeneca has been criticised by the European Union for its supply of shots, and is being sued by the bloc. The vaccine has also faced age restrictions due to rare clots linked to the vaccine and its application for U.S. approval is longer than expected.

Chief Executive Pascal Soriot said he had no regrets over getting involved in COVID-19 vaccines as the company has made an “enormous difference”.

It has delivered one billion doses around the world globally and is celebrated by the British government as a national success story of the pandemic.

Dobber said that AstraZeneca’s “number one commitment” was to deliver hundreds of millions of vaccine doses that were covered by current contracts.

“It’s not a distraction,” he said.

He added that the company would keep its pledge to deliver a broadly available and accessible vaccine. Soriot has said that the vaccine will always be kept affordable for low-income countries, even when the company moves away from a no-profit model.

Results released on Thursday showed sales of the vaccine in the second quarter more than tripled to $894 million from the first three months of the year.

But, unlike for rivals including Pfizer, it remains a drag on earnings overall, and Dobber said that if the vaccine business were to be sustainable, the company would have to stop making a loss on it.

“It doesn’t mean that moving forward we will not make a bit of profit,” Dobber said. “It’s not sustainable to do it without profits, but it’s too early now to speculate about that.”

(Reporting by Alistair Smout in London and Pushkala Aripaka in Bengaluru; Editing by Jason Neely, Josephine Mason and Jan Harvey)

Stronger Pound Weighs on FTSE 100 as June Inflation Jumps

The blue-chip FTSE 100 index slid 0.3%, with travel stocks down nearly 0.7%. Retailers Unilever, GlaxoSmithKline, and Diageo were among the top drags as the pound rose after inflation jumped to its highest in almost three years.

The domestically focussed mid-cap index fell 0.4%, with Cineworld being the top loser.

British inflation rose further above the Bank of England’s target in June at 2.5%, up from 2.1% in May, led by higher prices for food, fuel, second-hand cars, clothing, and footwear, official data showed on Wednesday.

That pushed UK’s benchmark 10-year bond yields up by five basis points, but the central bank’s comments that said the spike is likely to be transitory helped curb further losses.

“We’re still stuck in an inflationary limbo, where we can’t tell if rising prices are a statistical blip, or a more concerning and permanent feature of the global economic recovery,” said Laith Khalaf, a financial analyst at AJ Bell.

The blue-chip FTSE 100 has gained nearly 10% so far this year, supported by cheap interest rates, but its pace of growth has slowed since June to trade range-bound near the 7,100 level as higher COVID-19 cases and inflation weighed on investor mood.

Among stocks, AstraZeneca lost 0.7% and was the top drag on the FTSE 100. UK’s competition regulator cleared its $39 billion buyout of U.S.-based Alexion.

Barratt Developments gained 1.3% after it forecast 2021 profit to be marginally above the top end of market expectations.

Snack food firm SSP Group tumbled 2.7% on its chief executive officer’s plans to step down from his role at the end of 2021 to join a private equity-backed business.

For a look at all of today’s economic events, check out our economic calendar.

(Reporting by Shashank Nayar in Bengaluru; Editing by Subhranshu Sahu and Uttaresh.V)


Mining, Healthcare Stocks Boost FTSE 100 as Economy Strengthens

The blue-chip index rose 0.3%, with precious metal miners and base metal miners jumping 2% and 1.4%, respectively.

Pharmaceutical stocks also rose, with AstraZeneca leading the gains.

The domestically focused mid-cap FTSE 250 index advanced 0.3%.

The UK economy in April was a record 27.6% larger than 12 months before, official data showed, an increase that reflects recent reopening and the scale of disruption to everyday life early in the COVID-19 pandemic. In April alone, output rose by 2.3%, marking the fastest growth since July.

Among other stocks, Sanne Group jumped 11.5% as the asset management services provider said it was in talks with Cinven after the private-equity firm made a sweetened offer of 875 pence per share to buy the company.

For a look at all of today’s economic events, check out our economic calendar.

(Reporting by Devik Jain in Bengaluru; editing by Uttaresh.V)


Uk Competition Regulator Looking Into $39 Billion Astrazeneca-Alexion Deal

The UK’s Competition and Markets Authority (CMA) said on Tuesday it was inviting comments from any interested party on the deal to help its assessment, setting a deadline of June 3 for any submissions.

Anglo-Swedish drugmaker AstraZeneca, also a major COVID-19 vaccine producer, agreed to buy Alexion in December in its largest ever deal in a bet on rare-disease and immunology drugs and to diversify away from its fast-growing cancer business.

Cambridge, UK-based AstraZeneca’s shareholders approved the proposal at a general meeting earlier this month.

The United States has cleared the deal, as have other countries including Canada, Brazil and Russia.

“The commencement of the UK CMA’s formal review is another important step towards closing of the proposed acquisition, which we continue to expect will be in the third quarter of 2021,” a representative for AstraZeneca said.

Alexion did not immediately respond to a request for comment.

It’s best-selling drug Soliris is used against a range of rare immune-disorders including paroxysmal nocturnal hemoglobinuria (PNH), which causes anaemia and blood clots.

AstraZeneca hopes an improved version of the drug has even larger market potential. It expects to boost growth by introducing Alexion’s rare-disease medicines to China and other emerging markets.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Devika Syamnath, Kirsten Donovna)

Oxford Biomedica Lifts Outlook as AstraZeneca Ramps Up Vaccine Output

Shares of the cell therapy firm, which has an agreement to mass-produce AstraZeneca’s COVID-19 vaccine, rose 6.2% in early trading.

Oxford Biomedica raised its forecast for cumulative revenues from AstraZeneca by end-2021 to more than 100 million pounds ($141.82 million) from more than 50 million pounds earlier. The company did not provide any other details on its deal.

Liberum analysts said the increased supply deal was a “huge endorsement” of Oxford Biomedica’s capabilities, and that a further extension from AstraZeneca feels “increasingly likely”.

AstraZeneca has had a bruising start to the year as it struggled with vaccine production and faced a legal battle after cutting deliveries to Europe.

Oxford Biomedica was spun off in 1995 from the University of Oxford, which developed the COVID-19 vaccine before licensing it to AstraZeneca in April 2020.

The company, which signed the 18-month supply deal with AstraZeneca in September 2020, did not immediately respond to a Reuters request for a comment.

($1 = 0.7051 pounds)

(Reporting by Vishwadha Chander in Bengaluru; Editing by Devika Syamnath)

EU Sues AstraZeneca over Delayed Deliveries of COVID-19 Vaccine

AstraZeneca said in response that the legal action by the EU was without merit and pledged to defend itself strongly in court.

“AstraZeneca has fully complied with the Advance Purchase Agreement with the European Commission and will strongly defend itself in court. We believe any litigation is without merit and we welcome this opportunity to resolve this dispute as soon as possible,” AstraZeneca said in a statement on Monday.

Under the contract, the Anglo-Swedish company had committed to making its “best reasonable efforts” to deliver 180 million vaccine doses to the EU in the second quarter of this year, for a total of 300 million in the period from December to June.

But AstraZeneca said in a statement on March 12 it would aim to deliver only one-third of that by the end of June, of which about 70 million in the second quarter. A week after that, the Commission sent a legal letter to the company in the first step of a formal procedure to resolve disputes.

“The Commission has started last Friday a legal action against AstraZeneca,” the EU spokesman told a news conference, noting all 27 EU states backed the move.

“Some terms of the contract have not been respected and the company has not been in a position to come up with a reliable strategy to ensure timely delivery of doses,” the spokesman said, explaining what triggered the move.

Under the contract, the case will need to be resolved by Belgian courts.

“We want to make sure there is a speedy delivery of a sufficient number of doses that European citizens are entitled to and which have been promised on the basis of the contract,” the spokesman said.

“Every vaccine dose counts,” EU health commissioner Stella Kyriakides said on Twitter, announcing the legal proceedings against AstraZeneca.

Germany, France and Hungary were among EU states that were initially reticent to sue the company, diplomats said, but eventually they supported the move.

The EU wants AstraZeneca to deliver the promised 300 million doses, but in a further sign of its irritation towards the company, it has already forgone another 100 million shots that it had an option to buy under the contract signed in August.

(Reporting by Francesco Guarascio; additional reporting by Marine Strauss; Editing by Alex Richardson and Bernadette Baum)

Oxford COVID-19 Vaccine Tech Maker Vaccitech Targets $613 Million Valuation in U.S. IPO

The company, which has development programs for conditions including hepatitis B, prostate cancer and non-small cell lung cancer, has raised $216 million to date from Gilead Sciences, Sequoia Capital China and Oxford Sciences Innovation among others.

The UK-based company, spun out of Jenner Institute at the Oxford University in 2016, said it plans to list its American Depositary Shares (ADS) on Nasdaq under the ticker symbol “VACC”.

It said it was offering 6.5 million ADSs, each representing one ordinary share, priced between $16 and $18 each. At the top end of the range, the IPO would rake in $117 million for Vaccitech.

The company intends to use proceeds from the offering to fund its ongoing clinical programs and its early-stage research and development.

Morgan Stanley, Jefferies, Barclays, William Blair and H.C. Wainwright & Co are the underwriters for the offering.

(Reporting by Niket Nishant and Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)

Stocks Mixed After Inflation Exceeds Analyst Expectations

Inflation Rate Increased By 2.6% In March

The U.S. has just released Inflation Rate and Core Inflation Rate reports. The reports indicated that Inflation Rate increased by 2.6% year-over-year in March compared to analyst consensus which called for growth of 2.5%. Core Inflation Rate increased by 1.6% year-over-year compared to analyst consensus of 1.5%.

Inflation is moving higher on a year-over-year basis as prices were weak during the acute phase of the coronavirus crisis a year ago. Inflation looks more calm on a month-over-month basis although it also exceeded analyst expectations. Inflation Rate grew by 0.6% month-over-month in March compared to analyst consensus of 0.5%, while Core Inflation Rate increased by 0.3%.

S&P 500 futures are swinging between gains and losses in premarket trading after the release of inflation reports. Meanwhile, Treasury yields failed to gain additional upside momentum after reports indicated that inflation exceeded analyst expectations.

U.S. Recommends Pausing The Use Of Johnson & Johnson’s COVID-19 Vaccine

Shares of Johnson & Johnson found themselves under pressure in premarket trading after U.S. health agencies called for a temporary pause of the use of the company’s coronavirus vaccine.

The problems of Johnson & Johnson are similar to AstraZeneca‘s problems. In rare cases, recipients of the vaccine developed blood clots.

While these cases are extremely rare, the negative headlines may decrease people’s confidence in vaccination in general, so Johnson & Johnson’s problems may serve as a bearish catalyst for the market.

Euro Area Economic Sentiment Declines

Today, EU reported that Euro Area ZEW Economic Sentiment Index decreased from 74 in March to 66.3 in April. Analysts expected that it would grow to 77. In Germany, Economic Sentiment Index declined from 76.6 to 70.7 compared to analyst consensus of 79.

The reports indicated that European businesses have started to feel the pressure from the third wave of the virus. At the same time, it should be noted that ZEW Economic Sentiment Index remains at high levels.

For a look at all of today’s economic events, check out our economic calendar.

What is next for US stock market and dollar?

SP500 index is now up more than +9% year-to-date, while the Dow is up +9.5% and the Nasdaq is up more than +7%. Bulls remain committed to their outlook for an economic boom, all of which is underpinned by the U.S. Federal Reserve’s continued easy monetary policies.

Fundamental analysis

Federal Reserve and monetary policy

Federal Reserve Chairman Jerome Powell reiterated last week that the Fed would continue to remain extremely accommodative until the economy has further recovered. Speaking during an IMF event, Powell pointed out that while parts of the economy are recovering strongly, “there’s a very large group of people who are not.”

The Fed Chair acknowledged the better than expected job gains in March and said the Fed would consider a string of similar monthly gains to progress. Also, Powell again pointed to the weak labor market participation rate as a disinflationary force that will keep temporary price spikes under control. What Powell seems more concerned about is the ongoing pandemic and rising infections across many parts of the world, noting that the “world economy” can’t return to normal until the virus is under control everywhere.


Keep in mind, many of our largest U.S. businesses get +40% or more of their revenue from the global economies. Obviously, it is going to take more widespread vaccination and better efforts in other countries to orchestrate a global recovery. The U.S. remains one of the leaders in vaccinations but there might be a little hiccup the next week or two, as Johnson & Johnson has run into some manufacturing snafus. The CDC said -85% fewer doses of the company’s vaccine will be shipped to states next week, though they did not provide a reason.

Around 15 million J&J doses had to be destroyed because of an ingredient mix up at a factory late last month. Traders are also keeping an eye on developments surrounding AstraZeneca’s Covid-19 vaccine which has been suspended in several country’s due to a possible link to blood clots. Unfortunately, the AstraZeneca drug is the dominant vaccine in use across the globe because of its lower cost and easier distribution. Most advanced economy countries that are using AstraZeneca’s drug also have vaccine supplies from other drug makers but the suspension will still mean a slowdown for vaccine rollouts in many parts of Europe and Asia.

AstraZeneca’s safety issues could mean no vaccine supplies at all for some developing countries where it’s the only option. An underlying concern is that these compounding safety issues, shot suspensions, and other hiccups could lead to an overall “crisis of confidence” in vaccine campaigns, meaning fewer people getting inoculated and delaying the global end to the pandemic.

News and data to watch

Next week brings the Consumer Price Index on Tuesday; Import/Export Prices and the Fed’s Beige Book on Wednesday; Empire State Manufacturing, Retail Sales, Industrial Production, Business Inventories, and the NAHB Housing Market Index on Thursday; and Housing Starts on Friday.

The main focus next week will likely be on Q1 earnings, with the season “unofficially” kicking off with results from big Wall Street banks Goldman Sachs, JPMorgan Chase, and Wells Fargo on Wednesday, followed by Bank of America, Citigroup, and U.S. Bancorp on Thursday.

SP500 technical analysis

sp500 technical analysis

So far SP500 futures still didn’t break above Gann’s resistance. Yet the weekly closing looks very strong. But we can consider longs at this stage only if this resistance turns into support. In that case, 4250 is the natural magnet. However, I am a bit skeptical it may happen.

I like to trade SP500 when Advance Decline Line and cycles give the same signal. At the moment, it is better to pay attention to commodities. There are few markets ready for big moves. At the same time, SP500 cycles turned to the downside, while ADL is very bullish. If we will see a divergence in ADL in coming week or two, I will look for a sell signal. But at the moment, nothing is clear yet.

Dollar Index (DXY) technical analysis

dollar forecast

Overall, the Federal Reserve policy remains bearish for American currency in the long run. But we don’t have a strong fundamental setup to establish swing trades. So, I want you to pay attention to the smaller time frame. The dollar index (DXY) respects 4h MA50 and MA200 quite well. So, we can take advantage of that.

If the price breaks and sustains under 91.90, the price will reach 91.5 and 91 in extension. On the other hand, breaching the 4h MA50, the dollar will target the 93 – 93.5 zone.

For a look at all of today’s economic events, check out our economic calendar.

Sterling Stems Losses Versus Dollar, After Hard Profit-Taking Knock

By Tom Wilson

The pound slumped 0.6% to a one-week low against the dollar and around 1% against the euro on Wednesday as investors took cash off the table after a strong first quarter for the British currency.

But by 0847 GMT on Thursday, sterling was flat against the dollar at $1.3725, according to Yahoo! Finance, having touched its lowest this month a day earlier.

Against the euro, it traded down slightly at 86.42 pence per euro, according to Yahoo! Finance, after its worst day against the single currency in five weeks.

ING analysts wrote that sterling’s pullback was “exaggerated,” adding that they “remain constructive on the currency”, citing Britain’s relatively fast coronavirus vaccine programme.

Expectations of an economic rebound in Britain, spurred by rapid COVID-19 vaccinations, helped sterling to record its best quarter since 2015 versus the euro.

Diminishing expectations that the Bank of England will push interest rates to negative territory have also helped.

Britain has surged ahead of the rest of Europe in the race to inoculate its population, with almost half of its citizens receiving a first dose. But supply issues from its main Oxford-AstraZeneca vaccine have slowed progress in recent days.

(Reporting by Tom Wilson; Editing by Mark Heinrich)

Germany to Discuss AstraZeneca COVID Shots After Blood Clot Reports

By Patricia Weiss and Caroline Copley

Health Minister Jens Spahn will talk with his regional counterparts at 1800 CET (1600 GMT), a ministry spokesman said.

The meeting follows further reports by Germany’s vaccine regulator, the Paul Ehrlich Institute (PEI), of cases of blood clots known as cerebral sinus vein thrombosis (CSVT).

Germany’s vaccine committee, known as STIKO, will recommend using the Anglo-Swedish shot only in people over 60, the Augsburger Allgemeine newspaper reported citing a draft decision by STIKO.

PEI said it had registered 31 cases of CSVT, which resulted in nine deaths, out of some 2.7 million people who have received the AstraZeneca vaccine. With the exception of two cases, all reports involved women aged between 20 and 63.

It did not comment on the possible consequences and only said it was actively working with the European Medicines Agency (EMA). EU regulators plan to issue an updated recommendation on the AstraZeneca shot next week.

Several German states, including Berlin and Brandenburg, as well as the city of Munich, said they would stop giving the shot to people under 60.

State hospital groups Charite and Vivantes suspended vaccinations in female staff aged under 55, citing further cases of CSVT.

“Although no complications have occurred at the Charite after vaccinations with AstraZeneca, the Charite wants to take precautionary action here and wait for final assessments,” a spokeswoman said.

Because use of the vaccine in Germany was initially limited to those under 65, the shot has been administered among younger women, particularly medical staff and teachers.

Many European countries briefly stopped using the Anglo-Swedish firm’s vaccine earlier this month while investigating rare cases of blood clots.

Both the EMA and the World Health Organization said this month the benefits of AstraZeneca’s vaccine outweighed the risks.

An EMA review covering 20 million people who took the AstraZeneca shot in Britain and the European Economic Area found seven cases of blood clots in multiple blood vessels and 18 cases of CVST.

AstraZeneca says its vaccine is safe and effective, citing extensive trial data. Millions of doses have been safely administered around the world.

Nearly all countries have since resumed use of the vaccine. But France broke with guidance from the EMA and said on March 19 it should only be given to people aged 55 or older. France said the decision was based on evidence that the clotting affected younger people.

Canadian Health Officials said on Monday they would stop offering AstraZeneca’s shot to people under 55 and require a new analysis of the shot’s benefits and risks based on age and gender.

Some 19,000 people work at the Charite hospitals and 17,000 at Vivantes, which operates clinics as well as care homes.

Tagesspiegel, which first reported the decision, said that around two thirds of staff at Charite have been vaccinated so far, and 70% of those workers have received one shot of the AstraZeneca vaccine.

Bavarian Premier Markus Soeder criticised the “back and forth” around the vaccine, saying all recommendations showed that the danger of severe illness from the coronavirus outweighed any side-effects linked to the shot.

“At some point we have to be able to administer it freely and say, ‘he who wants it and he who dares should be able to get it’,” he said.

(Reporting by Caroline Copley and Patricia Weiss; Editing by Nick Macfie)

Oil Bears Reign Despite Blockage at Suez Canal

At press time, the British-based contract Brent crude futures lost over 1% to trade at $63 a barrel after jumping substantially yesterday.

Sequel to the Suez Canal blockage, oil prices had lately been under immense selling pressures as the black viscous hydrocarbon lost about 5% in value, breaching below $65 a barrel on fears about tighter COVID-19 curbs in key emerged markets and of late the suspension of vaccine usage in Western Europe.

Also recent revelation from a U.S health regulator points that AstraZeneca vaccine could have included outdated information in its data, stunned oil traders in staying long relatively.

Such macros altered the bulls’ run momentarily and sharply reversed yesterday’s gain on news of the blockage in the Suez Canal, potentially obstructing oil tankers carrying about 13 million barrels of oil.

Consequently, recent price actions reveal oil traders are reacting more to demand risks rather than supply dynamics even as oil vessels carrying Russian, Saudi, Omani and US crude wait on, meaning it could be just a matter of few weeks for Brent crude bears to test the $60 support levels.

The soaring value in the U.S dollar in recent times further compounds the precarious situation oil bulls are currently in, as recent data from the U.S dollar index reveal investors presently prefer to hold the safe-haven currency, rather than holding riskier assets like commodities.

In line with broader market sentiments, oil bulls are under siege as Covid-19 concerns batter hard on oil prices, OPEC+ April 1 meeting might see a rollover of their current supply curbs into May.

For a look at all of today’s economic events, check out our economic calendar.